Taking cellular immunotherapy to the next level

Glycostem Therapeutics is an innovator in allogeneic cellular immunotherapy using Natural Killer (NK) cells - oNKord® - or antigen presenting cells - sDCord® - for treatment of leukemia, lymphoma and solid tumors.

Find out more


Glycostem is a clinical-stage company, harvesting the power of allogeneic cells like Natural Killer (NK) cells - oNKord® - or antigen presenting cell - sDCord® - in the field of cellular immunotherapy. Using our proprietary expansion and differentiation platform, we produce large amounts of effector cells from Umbilical Cord Blood stem cells. Products are composed of high-quality, pure and active cells.

NK cells will be the new star in the domain of cellular immunotherapy. Due to their tightly regulated “natural killing", caused by a changed balance between activating and inhibitory cellular signals and antibody dependent cellular cytotoxicity (ADCC).

NK cells have the capability to control viral infections, target cancer and kill senescent cells. Unfortunately, our immune system can be compromised, allowing tumor cells to escape the immunological control mechanisms. Allogeneic conditions will be able to mitigate this problem. Glycostem's therapeutic concept and product pipeline is based on this principle.

Recently, the lead product - oNKord® - has been tested for safety and efficacy in a phase I study with Acute Myeloid Leukemia (AML) patients. oNKord® showed no toxicity, expanded in vivo, migrated to the bone marrow and killed leukemic blasts.

3U picture

Why allogeneic NK cells?

NK cells are manufactured from an unlimited source of umbilical cord blood hematopoietic stem cells. As NK cells mediate potent anti-tumor responses without attacking healthy tissues enables an universal donor principle (allogeneic approach). The use of NK cells is unrestricted as they are able to kill various types of cancer cells.

Natural Killer Cells >

Clinical study

oNKord® has been tested in patients suffering from Acute Myeloid Leukemia (AML) for safety, efficacy and biological functions.

Phase I clinical trial >